HUP0104302A2 - Inhibition of the formation of vascular hyperpermeability - Google Patents
Inhibition of the formation of vascular hyperpermeabilityInfo
- Publication number
- HUP0104302A2 HUP0104302A2 HU0104302A HUP0104302A HUP0104302A2 HU P0104302 A2 HUP0104302 A2 HU P0104302A2 HU 0104302 A HU0104302 A HU 0104302A HU P0104302 A HUP0104302 A HU P0104302A HU P0104302 A2 HUP0104302 A2 HU P0104302A2
- Authority
- HU
- Hungary
- Prior art keywords
- tyrosine kinase
- vascular hyperpermeability
- formation
- vascular
- inhibition
- Prior art date
Links
- 230000002792 vascular Effects 0.000 title abstract 4
- 230000015572 biosynthetic process Effects 0.000 title abstract 2
- 230000005764 inhibitory process Effects 0.000 title 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 abstract 2
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 abstract 1
- 206010051392 Diapedesis Diseases 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 206010015866 Extravasation Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 206010030113 Oedema Diseases 0.000 abstract 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 1
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 abstract 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 abstract 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 abstract 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 abstract 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 210000002808 connective tissue Anatomy 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000036251 extravasation Effects 0.000 abstract 1
- 239000012530 fluid Substances 0.000 abstract 1
- 230000009931 harmful effect Effects 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 230000035790 physiological processes and functions Effects 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
- 210000004243 sweat Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
Abstract
A vaszkuláris hiperpermeabilitás számos olyan élettani történésbevezetője, amelyek gyakran káros hatással vannak a szervezetre. Azilyen történések közé tartoznak az ödémaképződés, a diapedezis, azérbelhártyán át zajló cserefolyamatok zavara, az extravazáció, abeszűrődések és izzadmányok, a kötőszövet közötti lerakódások (gyakrana sztróma abnormális proliferációjával társulva) és a vaszkulárishipotenzió. A vaszkuláris hiperpermeabilitás és az azt követőtörténések megakadályozhatók egy olyan vegyület beadásával, amely aVEGF tirozin-kináz-receptor (amely KDR tirozin-kináz néven is ismert)enzimaktivitását gátolja. Az előnyös vegyületek szelektíven gátolják aKDR tirozin-kináz működését, de nem gátolják az Flt-1 tirozin-kinázt,ami egy másik VEGF tirozin-kináz-receptor. ÓVascular hyperpermeability is an introduction to many physiological events that often have a harmful effect on the body. Such events include the formation of edema, diapedesis, disruption of exchange processes across the acetabular membrane, extravasation, fluid secretions and sweats, deposits between the connective tissue (often associated with abnormal proliferation of the stroma) and vascular hypertension. Vascular hyperpermeability and its sequelae can be prevented by administration of a compound that inhibits the enzyme activity of the VEGF receptor tyrosine kinase (also known as KDR tyrosine kinase). Preferred compounds selectively inhibit KDR tyrosine kinase, but do not inhibit Flt-1 tyrosine kinase, another VEGF tyrosine kinase receptor. HE
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10746298P | 1998-11-06 | 1998-11-06 | |
PCT/US1999/025903 WO2000027414A2 (en) | 1998-11-06 | 1999-11-03 | Inhibition of the formation of vascular hyperpermeability |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0104302A2 true HUP0104302A2 (en) | 2002-03-28 |
HUP0104302A3 HUP0104302A3 (en) | 2002-11-28 |
Family
ID=22316735
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0104302A HUP0104302A3 (en) | 1998-11-06 | 1999-11-03 | Inhibition of the formation of vascular hyperpermeability |
Country Status (19)
Country | Link |
---|---|
EP (1) | EP1126842A2 (en) |
JP (1) | JP2002529421A (en) |
KR (1) | KR20010080952A (en) |
CN (1) | CN1342077A (en) |
AR (1) | AR023912A1 (en) |
AU (1) | AU1908000A (en) |
BG (1) | BG105476A (en) |
BR (1) | BR9915139A (en) |
CA (1) | CA2347916A1 (en) |
CO (1) | CO5150183A1 (en) |
CZ (1) | CZ20011564A3 (en) |
HU (1) | HUP0104302A3 (en) |
ID (1) | ID29063A (en) |
IL (1) | IL142583A0 (en) |
NO (1) | NO20012218L (en) |
PL (1) | PL348163A1 (en) |
SK (1) | SK5052001A3 (en) |
TR (1) | TR200102278T2 (en) |
WO (1) | WO2000027414A2 (en) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL143596A0 (en) | 1998-12-22 | 2002-04-21 | Genentech Inc | Vascular endothelial cell growth factor antagonists and uses thereof |
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
EP1158985B1 (en) | 1999-01-13 | 2011-12-28 | Bayer HealthCare LLC | OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS |
ES2303514T3 (en) * | 1999-12-22 | 2008-08-16 | The Scripps Research Institute | MODULATORS AND INHIBITORS OF ANGIOGENESIS AND VASCULAR PERMEABILITY. |
DE10021246A1 (en) * | 2000-04-25 | 2001-10-31 | Schering Ag | New N-substituted benzamide derivatives are tyrosine kinase KDR and FLT inhibitors useful e.g. for treating tumors, psoriasis, rheumatoid arthritis, diabetic retinopathy or liver sclerosis |
CA2454976C (en) * | 2001-07-26 | 2011-05-10 | Santen Pharmaceutical Co., Ltd. | Therapeutic agent for glaucoma comprising compound having pi3 kinase inhibitory action as active ingredient |
PT1478358E (en) | 2002-02-11 | 2013-09-11 | Bayer Healthcare Llc | Sorafenib tosylate for the treatment of diseases characterized by abnormal angiogenesis |
US7261876B2 (en) | 2002-03-01 | 2007-08-28 | Bracco International Bv | Multivalent constructs for therapeutic and diagnostic applications |
EP1587944A4 (en) | 2002-03-01 | 2007-03-21 | Dyax Corp | Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy |
US7794693B2 (en) | 2002-03-01 | 2010-09-14 | Bracco International B.V. | Targeting vector-phospholipid conjugates |
US8623822B2 (en) | 2002-03-01 | 2014-01-07 | Bracco Suisse Sa | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy |
WO2006006948A2 (en) | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
EP2213738B1 (en) * | 2002-11-14 | 2012-10-10 | Dharmacon, Inc. | siRNA molecules targeting Bcl-2 |
DK2949658T3 (en) | 2003-03-03 | 2018-10-01 | Dyax Corp | Peptides that specifically bind HGF receptor (cMet) and uses thereof |
DE602004011340T2 (en) | 2003-05-20 | 2008-11-06 | Bayer Healthcare Llc | DIARYL-UREA SUBSTANCES WITH CHINESE-INHIBITING EFFECT |
UA84156C2 (en) | 2003-07-23 | 2008-09-25 | Байер Фармасьютикалс Корпорейшн | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
RU2542471C2 (en) * | 2006-11-15 | 2015-02-20 | Коуда Терапьютикс, Инк. | Improved methods and compositions for wound healing |
MX2013000986A (en) | 2010-07-28 | 2013-07-03 | Alcon Res Ltd | Sirna targeting vegfa and methods for treatment in vivo. |
KR101565886B1 (en) | 2013-10-23 | 2015-11-05 | 전남대학교산학협력단 | Method and Kit for Diagnosting of Ovarian Hyperstimulation Syndrome |
EA201790434A1 (en) | 2014-08-22 | 2017-07-31 | Окленд Юнисервисиз Лимитед | CHANNEL MODULATORS |
CN106381330A (en) * | 2016-08-30 | 2017-02-08 | 张建华 | Primer and kit for detecting susceptibility of communicating hydrocephalus |
KR102644938B1 (en) * | 2018-03-19 | 2024-03-07 | 주식회사 파멥신 | Anti-vegfr-2 antibody |
CN109718253B (en) * | 2019-01-16 | 2021-09-24 | 中国人民解放军总医院 | Use of bacteria capable of metabolizing to produce histamine for preventing or treating altitude sickness |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE789948A (en) * | 1971-10-13 | 1973-04-11 | Sandoz Sa | NEW DERIVATIVES OF PYRAZOLE, THEIR PREPARATION AND THEIR APPLICATION AS MEDICINAL PRODUCTS |
US3843664A (en) * | 1973-02-20 | 1974-10-22 | Sandoz Ag | Substituted naphtho pyrazoles |
US3843665A (en) * | 1973-04-11 | 1974-10-22 | Sandoz Ag | Process for preparing substituted indeno,naphtho and cyclohepta pyrazoles |
US3843666A (en) * | 1973-05-29 | 1974-10-22 | Sandoz Ag | Process for preparing substituted indeno,naphtho and cyclohepta pyrazoles |
US5712395A (en) * | 1992-11-13 | 1998-01-27 | Yissum Research Development Corp. | Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis |
WO1998033917A1 (en) * | 1994-11-14 | 1998-08-06 | The Ludwig Institute For Cancer Research | Vascular endothelial growth factor c (vegf-c) protein and gene, mutants thereof, and uses thereof |
US6346398B1 (en) * | 1995-10-26 | 2002-02-12 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor |
FR2742662B1 (en) * | 1995-12-21 | 1998-01-23 | Centre Nat Rech Scient | ANTI-IDIOTYPIC ANTIBODIES OF VASCULAR ENDOTHELIAL GROWTH FACTOR AND THEIR USE AS MEDICAMENTS |
US6100071A (en) * | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
DE19638745C2 (en) * | 1996-09-11 | 2001-05-10 | Schering Ag | Monoclonal antibodies against the extracellular domain of the human VEGF receptor protein (KDR) |
JP4405597B2 (en) * | 1997-06-18 | 2010-01-27 | メルク エンド カムパニー インコーポレーテッド | Human receptor tyrosine kinase KDR |
EP1021182A1 (en) * | 1997-10-06 | 2000-07-26 | Basf Aktiengesellschaft | Indeno[1,2-c] pyrazole derivatives for inhibiting tyrosine kinase activity |
DE69818083T2 (en) * | 1997-10-06 | 2004-07-08 | Abbott Gmbh & Co. Kg | INDENO [1,2-c] -, NAPHTHO [1,2-C] AND BENZO [6,7] CYCLOHEPTA [1,2-c] PYRAZOLE DERIVATIVES |
CN1311678A (en) * | 1998-04-30 | 2001-09-05 | 巴斯福股份公司 | Substituted tricyclic pyrazole derivatives with protein kinase activity |
-
1999
- 1999-11-03 SK SK505-2001A patent/SK5052001A3/en unknown
- 1999-11-03 PL PL99348163A patent/PL348163A1/en unknown
- 1999-11-03 CN CN99812924A patent/CN1342077A/en active Pending
- 1999-11-03 JP JP2000580643A patent/JP2002529421A/en active Pending
- 1999-11-03 ID IDW00200101000A patent/ID29063A/en unknown
- 1999-11-03 WO PCT/US1999/025903 patent/WO2000027414A2/en not_active Application Discontinuation
- 1999-11-03 EP EP99962685A patent/EP1126842A2/en not_active Withdrawn
- 1999-11-03 CZ CZ20011564A patent/CZ20011564A3/en unknown
- 1999-11-03 AU AU19080/00A patent/AU1908000A/en not_active Abandoned
- 1999-11-03 HU HU0104302A patent/HUP0104302A3/en unknown
- 1999-11-03 TR TR2001/02278T patent/TR200102278T2/en unknown
- 1999-11-03 KR KR1020017005724A patent/KR20010080952A/en not_active Application Discontinuation
- 1999-11-03 IL IL14258399A patent/IL142583A0/en unknown
- 1999-11-03 CA CA002347916A patent/CA2347916A1/en not_active Abandoned
- 1999-11-03 BR BR9915139-1A patent/BR9915139A/en not_active IP Right Cessation
- 1999-11-05 AR ARP990105608A patent/AR023912A1/en unknown
- 1999-11-08 CO CO99070343A patent/CO5150183A1/en unknown
-
2001
- 2001-04-25 BG BG105476A patent/BG105476A/en unknown
- 2001-05-04 NO NO20012218A patent/NO20012218L/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20010080952A (en) | 2001-08-25 |
HUP0104302A3 (en) | 2002-11-28 |
NO20012218D0 (en) | 2001-05-04 |
CN1342077A (en) | 2002-03-27 |
BG105476A (en) | 2002-02-28 |
CO5150183A1 (en) | 2002-04-29 |
NO20012218L (en) | 2001-06-18 |
WO2000027414A3 (en) | 2000-09-08 |
WO2000027414A2 (en) | 2000-05-18 |
TR200102278T2 (en) | 2001-12-21 |
ID29063A (en) | 2001-07-26 |
PL348163A1 (en) | 2002-05-06 |
SK5052001A3 (en) | 2002-10-08 |
BR9915139A (en) | 2001-08-07 |
JP2002529421A (en) | 2002-09-10 |
IL142583A0 (en) | 2002-03-10 |
CZ20011564A3 (en) | 2002-04-17 |
CA2347916A1 (en) | 2000-05-18 |
AR023912A1 (en) | 2002-09-04 |
EP1126842A2 (en) | 2001-08-29 |
AU1908000A (en) | 2000-05-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0104302A2 (en) | Inhibition of the formation of vascular hyperpermeability | |
MA28038A1 (en) | THIENOPYRAZOLES | |
MY128370A (en) | Pyrrolotriazane inhibitors of kinases | |
AU2003282233A1 (en) | Quinoline derivatives as glucokinase ligands | |
TR200101859T2 (en) | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | |
EP0991628A4 (en) | QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR P56?lck TYROSINE KINASES | |
GEP20032958B (en) | Adenosine Derivatives | |
ATE302606T1 (en) | N-UREIDOALKYLPIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | |
BG105629A (en) | Quinoline and quinoxaline compounds | |
ES2108120T3 (en) | MONO- AND BICYCLE BIS ARYLIC AND HETEROARILIC COMPOUNDS INHIBITING EGF AND / OR PDGF TYPHOSINE KINASE. | |
MXPA02012712A (en) | N-ureidoheterocycloaklyl-piperidines as modulators of chemokine receptor activity. | |
NO995006D0 (en) | New connections | |
MY139999A (en) | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | |
RS50031B (en) | TRICYCLIC POLY INHIBITORS (ADP-Ribose) POLYMERASE | |
YU401A (en) | Agents with an antidepressive effect | |
NO984081L (en) | Pyrimido [5,4-d] pyrimidines, medicaments containing these compounds, their use and method of preparation thereof | |
CA2329636A1 (en) | Riluzole and levodopa combinations for treating parkinson's disease | |
GB9716219D0 (en) | Prevention of metastases | |
DK0888327T3 (en) | Benzopyran derivatives which have antagonistic action against leukotrienes | |
BR0113970A (en) | Pyrimidine compounds and their use | |
MXPA02007901A (en) | Modulation of bone formation. | |
WO2001091796A8 (en) | Methods, compounds and compositions for treating gout | |
DK0775118T3 (en) | Benzimidazole derivatives having dopaminergic activity | |
AU9139791A (en) | Use of quisqualate-receptor antagonists for treating Parkinson's disease | |
RU2003107920A (en) | KINASES SGK2 AND SGK3 AS TARGETS FOR DIAGNOSTIC AND THERAPEUTIC PURPOSES |